BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 19445623)

  • 1. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.
    Takata K; Kubota S; Fukata S; Kudo T; Nishihara E; Ito M; Amino N; Miyauchi A
    Thyroid; 2009 Jun; 19(6):559-63. PubMed ID: 19445623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relation of initial methimazole dose to the incidence of methimazole-induced agranulocytosis in patients with Graves' disease.
    Tsuboi K; Ueshiba H; Shimojo M; Ishikawa M; Watanabe N; Nagasawa K; Yuasa R; Yoshino G
    Endocr J; 2007 Feb; 54(1):39-43. PubMed ID: 17053291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
    Takata K; Amino N; Kubota S; Sasaki I; Nishihara E; Kudo T; Ito M; Fukata S; Miyauchi A
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis.
    Wall JR; Fang SL; Kuroki T; Ingbar SH; Braverman LE
    J Clin Endocrinol Metab; 1984 May; 58(5):868-72. PubMed ID: 6200492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
    Sato S; Noh JY; Sato S; Suzuki M; Yasuda S; Matsumoto M; Kunii Y; Mukasa K; Sugino K; Ito K; Nagataki S; Taniyama M
    Thyroid; 2015 Jan; 25(1):43-50. PubMed ID: 25178068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Re-administration of Low-dose of Methimazole (MMI) in Graves' Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU).
    Kubota S
    Intern Med; 2016; 55(22):3235-3237. PubMed ID: 27853063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment.
    Reinwein D; Benker G; Lazarus JH; Alexander WD
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1516-21. PubMed ID: 8501160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study.
    Mazza E; Carlini M; Flecchia D; Blatto A; Zuccarini O; Gamba S; Beninati S; Messina M
    J Endocrinol Invest; 2008 Oct; 31(10):866-72. PubMed ID: 19092290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of antihistamines after serious allergic reaction to methimazole in pediatric Graves' disease.
    Toderian AB; Lawson ML
    Pediatrics; 2014 May; 133(5):e1401-4. PubMed ID: 24777217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease.
    Watanabe N; Narimatsu H; Noh JY; Yamaguchi T; Kobayashi K; Kami M; Kunii Y; Mukasa K; Ito K; Ito K
    J Clin Endocrinol Metab; 2012 Jan; 97(1):E49-53. PubMed ID: 22049174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease.
    Nakamura H; Noh JY; Itoh K; Fukata S; Miyauchi A; Hamada N
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2157-62. PubMed ID: 17389704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan.
    Huang CN; Hsu TC; Chou HH; Tsay GJ
    J Formos Med Assoc; 2004 Apr; 103(4):274-9. PubMed ID: 15175822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment.
    Kobayashi S; Noh JY; Mukasa K; Kunii Y; Watanabe N; Matsumoto M; Ohye H; Suzuki M; Yoshihara A; Iwaku K; Sugino K; Ito K
    Thyroid; 2014 May; 24(5):796-801. PubMed ID: 24341564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The occurrence of agranulocytosis due to antithyroid drugs in a cohort of patients with Graves disease treated with radioactive iodine 131I during 14 years].
    Cepková J; Gabalec F; Svilias I; Horáček J
    Vnitr Lek; 2014 Oct; 60(10):832-6. PubMed ID: 25382005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Retrospective analysis of 18 cases with agranulocytosis induced by antithyroid drugs].
    Dai W; Zhang J; Zhan Z; Xu B; Jin H
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Jun; 20(3):226-9. PubMed ID: 11367711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methimazole-induced agranulocytosis in Japanese patients with Graves' disease.
    Tamai H; Takaichi Y; Morita T; Komaki G; Matsubayashi S; Kuma K; Walter RM; Kumagai LF; Nagataki S
    Clin Endocrinol (Oxf); 1989 May; 30(5):525-30. PubMed ID: 2605789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute pancreatitis induced by methimazole in a patient with Graves' disease.
    Yang M; Qu H; Deng HC
    Thyroid; 2012 Jan; 22(1):94-6. PubMed ID: 22136208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation.
    Yoshihara A; Noh J; Yamaguchi T; Ohye H; Sato S; Sekiya K; Kosuga Y; Suzuki M; Matsumoto M; Kunii Y; Watanabe N; Mukasa K; Ito K; Ito K
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2396-403. PubMed ID: 22547422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.